NantHealth Chairman and CEO Will Reveal How Advancements in AI and Machine Learning are Improving the Diagnosis and Treatment of Cancer
ORLANDO, FL – February 25, 2020: NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare technology company, announced today that Dr. Patrick Soon-Shiong, Chairman and CEO, has been chosen to keynote at the Intelligent Health™ Pavilion (IHP) during the Healthcare Information Management Systems Society (HIMSS) 2020 Annual Conference & Exhibition in Orlando. NantHealth is exhibiting at the show in booth #7366.
Dr. Soon-Shiong will share how AI technologies and machine learning can improve the diagnosis and treatment of cancer. This keynote address will highlight new clinical evidence and share compelling patient examples, while also revealing how clinicians can collaborate more effectively and access higher quality data to arrive at an accurate hypotheses/diagnosis faster.
What: “How Data is Revolutionizing Patient Outcomes”
Who: Dr. Patrick Soon-Shiong, Chairman and CEO of NantHealth
When: Tuesday, March 10 at 10:30 a.m. ET
Where: HIMSS Annual Conference & Exhibition | Intelligent Health Pavilion, Leadership Theatre | Orange County Convention Center | Orlando, Florida
The session will also be available for live viewing at https://info.nanthealth.com/himss20.
“We are excited and honored to have Dr. Patrick Soon-Shiong share his latest scientific findings, data advancements and patient stories with HIMSS and the entire healthcare community,” said Harry Pappas, Founder & CEO of the IHP. “This keynote will be a great opportunity to hear from a well-respected and proven healthcare and technology innovator on developments that are having a real impact on patients and the healthcare industry at large. Dr. Soon-Shiong and his NantHealth team are truly pioneering real change and influence in the area of personalized medicine.”
NantHealth will also feature several use cases highlighting its advanced data expertise in the IHP, including Eviti® Advisor, the most comprehensive digital library of unbiased, evidence-based oncology regimens and NaviNet® Open, a powerful payer-provider collaboration platform.
For more information visit, info.nanthealth.com/himss20
About NantHealth: NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payers, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payer/provider platforms that exchange information in near-real time (NaviNet and Eviti), and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer®). For more information, please visit nanthealth.com or follow us on Twitter, Facebook and LinkedIn.
Forward-Looking Statements: NantHealth
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.